Science & Technology

303 Items

Report

Tech and Public Policy to Save the Brain

    Authors:
  • Priyamvada Saraf
  • Mathew Alexander
  • Sohaib Nasim
  • Hardy Ding
| May 03, 2023

Neurodegenerative diseases (NDDs) represent a global health emergency, affecting millions of individuals and imposing significant economic burdens. Despite increased funding and government initiatives, effective therapies remain elusive, and NDD research lags behind other fields. This report argues for a simplified, accelerated, and transparent unified approach to NDD research, building on lessons from other fields and industries.

 display Discord

AP/Jeff Chiu, File

Analysis & Opinions - Belfer Center for Science and International Affairs, Harvard Kennedy School

Reactions to the Leak of Classified Military Intelligence Documents

Belfer Center experts on security, intelligence, and cybersecurity issues were interviewed on the recent leak of classified military intelligence documents allegedly by Airman Jack Teixeira.

Intel semicondictor

The National Interest

Analysis & Opinions - The National Interest

Intel Is Reeling: Why Should the Government Save It?

| Apr. 06, 2023

Why should Washington save Intel? The answer most frequently provided by policymakers is that the U.S. produces no advanced chips, putting it at risk of losing a conflict with China if Taiwan is unable to ship chips across the Pacific. In reality, this is a canard. Peter Wennink, CEO of Dutch lithography giant ASML, dispelled this myth in December, saying that “it is common knowledge that chip technology for purely military applications is usually 10, 15 years old.” America’s warfighting capability is not meaningfully undermined by its lack of production of advanced chips as even platforms like the F-35 fighter jet use only legacy chips.

teaser image

Blog Post - perspectives-on-public-purpose

Basic Science Research as the Pillar for NDD Drug Development

| Mar. 24, 2023

In the last decade, there has been a significant increase in the prevalence of neurodegenerative diseases (NDD) in the United States, affecting approximately 10.5 million individuals. This number is predicted to triple in the next 30 years.1 However, in comparison to other disease areas such as oncology, the approval of NDD drugs has been relatively limited. Our team has explored the NDD drug development ecosystem from three perspectives: stakeholders, funding, and policy. This article summarizes our key findings and presents a case study to suggest that the scarcity of new drug development may be attributable to insufficient basic scientific research. Finally, we outline our objectives for the upcoming semester.